Physician profile
Eduardo A Maraboto
NPI 1174871339
$4,218.25
in general payments reported to CMS, 2019-2025
24 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what 90% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $355 · 2023: $759 · 2024: $1,115 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,498.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $661.65 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $394.72 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $381.97 | 2023-2025 | Spravato |
| Lundbeck LLC | $345.06 | 2023-2025 | Rexulti, Vyepti |
| Teva Pharmaceuticals USA, INC. | $285.55 | 2024-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $276.74 | 2024-2025 | Auvelity, Sunosi |
| Inspire Medical Systems, INC. | $264.63 | 2023-2025 | Inspire |
| Genzyme Corporation | $237.39 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $197.78 | 2023-2025 | Rexulti |
| Abbott Laboratories | $167.36 | 2022-2023 | Proclaim |
| Genentech USA, INC. | $149.41 | 2022 | |
| Boston Scientific Corporation | $124.17 | 2025 | Watchman Flx |
| Kyowa Kirin, INC. | $115.36 | 2023 | |
| Sandoz INC. | $112.43 | 2025 | |
| Biogen, INC. | $93.12 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $87.67 | 2022 | |
| Acadia Pharmaceuticals INC | $84.52 | 2024-2025 | Nuplazid |
| Biosense Webster, INC. | $79.50 | 2024 | Carto 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $35.82 | 2024-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.96 | 2025 | Caplyta |
| Eisai INC. | $23.90 | 2023 | |
| Almatica Pharma LLC | $22.44 | 2021 | |
| Bioxcel Therapeutics, INC. | $22.04 | 2024 | Igalmi |
| Tms Neurohealth Centers INC. | $21.06 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduardo Maraboto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.